KRT17 and breast cancer: GPRC5A and KRT17 were overexpressed in pT1 and higher BC by 18.2-fold and 29.5-fold and in RPC by 9.6-fold and 18.8-fold compared to HC and NRT, however their expression was also elevated in DC including benign tumors and other type of cancers, therefore may be less specific to urothelial cancers but more general to tumors.